NYSEArca - Nasdaq Real Time Price USD

Capital Group Dividend Value ETF (CGDV)

36.21 -0.12 (-0.32%)
As of 3:11 PM EDT. Market Open.
Loading Chart for CGDV
DELL
  • Previous Close 36.33
  • Open 36.33
  • Bid 36.24 x 4000
  • Ask 36.25 x 3200
  • Day's Range 36.08 - 36.35
  • 52 Week Range 25.47 - 36.69
  • Volume 1,452,392
  • Avg. Volume 1,639,285
  • Net Assets 10.44B
  • NAV 36.48
  • PE Ratio (TTM) 25.16
  • Yield 1.43%
  • YTD Daily Total Return 23.11%
  • Beta (5Y Monthly) 0.00
  • Expense Ratio (net) 0.33%

Normally, the fund invests at least 80% of its assets in dividend-paying common stocks of larger, more established companies domiciled in the United States with market capitalizations greater than $4.0 billion. It may invest up to 10% of its assets in equity securities of larger companies domiciled outside the United States. The fund is non-diversified.

Capital Group

Fund Family

Large Value

Fund Category

10.44B

Net Assets

2022-02-22

Inception Date

Performance Overview: CGDV

View More

Trailing returns as of 9/27/2024. Category is Large Value.

YTD Return

CGDV
23.11%
Category
14.54%
 

1-Year Return

CGDV
39.69%
Category
21.17%
 

3-Year Return

CGDV
0.00%
Category
7.83%
 

People Also Watch

Holdings: CGDV

View More

Top 10 Holdings (39.13% of Total Assets)

SymbolCompany% Assets
MSFT
Microsoft Corporation 4.77%
RTX
RTX Corporation 4.50%
AAPL
Apple Inc. 4.36%
CARR
Carrier Global Corporation 4.26%
GE
GE Aerospace 4.12%
META
Meta Platforms, Inc. 4.08%
AIG
American International Group, Inc. 3.94%
PM
Philip Morris International Inc. 3.40%
UNH
UnitedHealth Group Incorporated 2.92%
TXN
Texas Instruments Incorporated 2.76%

Sector Weightings

SectorCGDV
Industrials   23.48%
Technology   16.35%
Healthcare   15.75%
Energy   4.34%
Utilities   3.48%
Real Estate   0.00%

Recent News: CGDV

View More

Research Reports: CGDV

View More
  • Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

    In this edition, trucking sector keeps on trucking; soft landing in sight for US economic outlook; a world of possibilities for Universal Music Group; and Accenture Plc, Koninklijke Philips NV, and Smartsheet.

     
  • Depressed Truckload Rates Keeping Hub Group's Intermodal Pricing Off Track

    Hub Group ranks among the largest providers of rail intermodal service. Roughly 60% of revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset light truck brokerage operations, along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub is somewhat acquisitive in that it often makes tuck-in acquisitions which expand its brokerage, last-mile, and dedicated offerings.

    Rating
    Price Target
     
  • Landstar's Operating Backdrop Conditions Stuck in Slow Lane, but Pricing Has Stabilized

    Landstar System is an agent based asset-light third-party logistics provider focused on domestic truck brokerage (90% of revenue). Historically, around half of its truck transportation freight is hauled by leased owner-operators with the remainder hauled by third-party broker-carriers. To a smaller degree, it offers intermodal, global air and ocean forwarding, and warehousing services. Landstar also runs a small business that offers insurance programs to captive owner-operators. It has a long history of industry-leading execution and operating profitability.

    Rating
    Price Target
     
  • Johnson & Johnson Earnings: Largely in Line as New Products Ready to Offset Stelara Biosimilars

    Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

    Rating
    Price Target
     

Related Tickers